/

Società

Ky

Non verificato

Kyowa Kirin International

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteScienza

3 comunicati stampa

Guarda tutti i comunicati

22/10/2025

Industria

Salute

Sanità

Scienza

Medicina - Varie

Farmaceutica

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)

Fonte

Kyowa Kirin International

Emittente

1.00

0

30/01/2025

Scienza

Biotecnologia

Farmaceutica

Oncologia

Salute

Medicina - Varie

Industria

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

Fonte

Kyowa Kirin International

Emittente

1.00

0

01/10/2024

Eventi

Fiere

Industria

Salute

Scienza

Farmaceutica

Medicina - Varie

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

Fonte

Kyowa Kirin International

Emittente

1.00

0

Seguaci

0

Compatibilità

0